Imphat Chureeporn, Woottisin Nanthakarn, Chiewsilp Wiwat
Applied Thai Traditional Medicine Program, School of Integrative Medicine, Mae Fah Luang University, Chiang Rai, 57100, Thailand.
Applied Thai Traditional Medicine Program, School of Integrative Medicine, Mae Fah Luang University, Chiang Rai, 57100, Thailand.
J Ayurveda Integr Med. 2025 May 21;16(3):101108. doi: 10.1016/j.jaim.2024.101108.
The essential oil from the pericarp (EOP) of Zanthoxylum rhetsa (Roxb.) DC. inhibits prostaglandin E, which is related to knee osteoarthritis (OA). However, there is no clinical report on its efficacy.
To assess the efficacy of EOP in Z. rhetsa (ZR) spray as a novel spray compared to diclofenac (DF) spray in elderly individuals diagnosed with primary knee OA.
60 patients with unilateral knee pain over three months were randomly assigned to either the ZR spray (experimental) or DF spray (control) group. Each group applied the spray topically 3 times daily (2 mL each time) for 14 consecutive days. Follow-ups occurred after day 7 and after day 14. Primary outcomes included pain score measurements, with secondary outcomes focusing on WOMAC index scores.
The ZR and DF spray groups did not significantly differ at baseline. ZR spray is the first to demonstrate non-inferior efficacy compared to DF spray, with no significant difference in the mean change of pain scores at rest after 10 min (effect size <0.2) and following a 20-m walk test (effect size <0.5), including walking time (effect size <0.2), as well as in WOMAC index scores (effect size <0.3) from baseline to the first and second visits. Additionally, patients treated with ZR spray required less oral medication from the first visit.
Analgesia and improved knee functionality provided by ZR spray are suitable for combined treatment in elderly patients with co-morbidities or limited oral NSAID medication due to increased risk.
刺花椒（Roxb.）DC.果皮的精油（EOP）可抑制与膝关节骨关节炎（OA）相关的前列腺素E。然而，尚无关于其疗效的临床报告。
评估与双氯芬酸（DF）喷雾剂相比，刺花椒（ZR）喷雾剂作为一种新型喷雾剂对诊断为原发性膝关节OA的老年人的疗效。
60例单侧膝关节疼痛超过3个月的患者被随机分为ZR喷雾剂（实验组）或DF喷雾剂（对照组）。每组每天局部使用喷雾剂3次（每次2 mL），连续使用14天。在第7天和第14天后进行随访。主要结局包括疼痛评分测量，次要结局重点关注WOMAC指数评分。
ZR和DF喷雾剂组在基线时无显著差异。ZR喷雾剂首次显示出与DF喷雾剂相比具有非劣效性疗效，在10分钟静息后疼痛评分的平均变化（效应量<0.2）以及20米步行试验后（效应量<0.5），包括步行时间（效应量<0.2），以及从基线到第一次和第二次访视时的WOMAC指数评分（效应量<0.3）方面均无显著差异。此外，接受ZR喷雾剂治疗的患者从第一次访视起所需的口服药物较少。
ZR喷雾剂提供的镇痛和改善膝关节功能适用于合并症老年患者或因风险增加而口服非甾体抗炎药受限的联合治疗。
